Eiger BioPharmaceuticals, Inc.
EIGRQ · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.01 | 0.04 | 0.05 |
| FCF Yield | -133.79% | -107.67% | -70.71% | -61.17% |
| EV / EBITDA | -2.21 | -1.64 | -2.55 | -3.04 |
| Quality | ||||
| ROIC | -47.13% | -43.04% | -35.70% | -29.42% |
| Gross Margin | 92.61% | 90.25% | 102.74% | 92.54% |
| Cash Conversion Ratio | 1.04 | 0.81 | 1.06 | 1.05 |
| Growth | ||||
| Revenue 3-Year CAGR | 22.90% | 41.87% | 94.72% | 2,462,214.78% |
| Free Cash Flow Growth | 4.12% | 34.00% | 8.96% | -7.79% |
| Safety | ||||
| Net Debt / EBITDA | -1.33 | -0.82 | -0.92 | -1.18 |
| Interest Coverage | -8.85 | -11.99 | -14.88 | -17.33 |
| Efficiency | ||||
| Inventory Turnover | 0.18 | 0.28 | -0.12 | 0.06 |
| Cash Conversion Cycle | -139.23 | -1,042.09 | 2,798.94 | -1,826.36 |